Liquid formulation of Vimpat relaunched

The antiepileptic Vimpat (lacosamide) has been relaunched by UCB Pharma and is now formulated as a lower strength syrup.

Vimpat syrup is unsuitable for patients with phenylketonuria
Vimpat syrup is unsuitable for patients with phenylketonuria

Vimpat (lacosamide) 10mg/ml syrup is indicated for the adjunctive treatment of partial onset-seizures with or without secondary generalisation in adults and children 16 years of age and older. The 10mg/ml syrup replaces the previous 15mg/ml formulation, which was recalled in 2011.

View Vimpat Syrup drug record

Further information: UCB Pharma Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from intelog

SGLT2 inhibitors: MHRA warns of Fournier's gangrene risk

SGLT2 inhibitors: MHRA warns of Fournier's gangrene risk

Cases of necrotising fasciitis of the genitalia or...

New advice for carbimazole over malformation and pancreatitis risks

New advice for carbimazole over malformation and pancreatitis risks

Reports of congenital malformations and acute pancreatitis...

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Potential sensitising agents in eye drops and ointments.

Antibiotic Treatments in Adults, Summary of Regimens

Antibiotic Treatments in Adults, Summary of Regimens

Dose regimens for common bacterial infections.